At least a dozen FDA-approved drugs trace their origins to ocean life, from sea sponges and cone snails to sea squirts and deep-sea bacteria. These aren’t experimental curiosities. Marine-derived drugs treat leukemia, breast cancer, lymphoma, chronic pain, and high triglycerides, and they’ve been entering medicine at an accelerating pace since the late 1960s.
The ocean’s extreme environments push marine organisms to produce unusual chemical compounds for defense, predation, and competition. Many of these molecules interact with human biology in ways that land-based organisms simply don’t, making the sea one of the richest sources of new drug leads in modern pharmacology.
Cancer Drugs From Sponges
The oldest marine drug still in widespread use is cytarabine, first isolated from a marine sponge and approved by the FDA in 1969. It remains a cornerstone treatment for acute leukemia more than five decades later, working by blocking the enzyme cells need to copy their DNA. When cancer cells can’t replicate their genetic material, they die. Two related drugs, vidarabine (approved 1976 for viral infections) and fludarabine (approved 1992 for certain blood cancers), were also developed from compounds first found in the same family of sea sponges.
A more recent sponge-derived drug is eribulin, sold as Halaven. It comes from a compound originally found in the Japanese marine sponge Halichondria okadai and was approved in 2010 for metastatic breast cancer. The natural compound, halichondrin B, was so structurally complex and scarce in nature that scientists had to develop a fully synthetic version for clinical use. Eribulin works by disrupting the internal scaffolding that cells need to divide, effectively freezing cancer cells mid-replication.
A Painkiller From Cone Snail Venom
One of the most striking examples of ocean pharmacology is ziconotide, brand name Prialt, approved in 2004. It is chemically identical to a 25-amino-acid peptide naturally produced by Conus magus, a small fish-hunting cone snail found in the Western Pacific. The snail uses this venom component to paralyze prey almost instantly.
In humans, the peptide blocks a specific type of calcium channel found at the endings of pain nerve fibers in the spinal cord. When these channels are blocked, pain signals still fire but never reach the brain, because the chemical messenger needed to relay the signal across the synapse can’t be released. This mechanism is completely different from opioids, making ziconotide a non-opioid option for severe chronic pain that hasn’t responded to other treatments. It’s delivered directly into spinal fluid, which limits its use to patients with truly intractable pain, but for those patients it can be transformative.
Sea Squirts and Lung Cancer
Sea squirts (tunicates) look like rubbery blobs anchored to rocks, but they’ve yielded some of the most potent anticancer compounds ever discovered. Trabectedin, one of the first tunicate-derived drugs to reach the market, is approved for soft tissue sarcomas and ovarian cancer in multiple countries. It works by binding directly to the minor groove of DNA, interfering with the machinery cancer cells use to read and repair their genetic code.
A newer relative, lurbinectedin (sold as Zepzelca), received FDA approval for extensive-stage small cell lung cancer, one of the most aggressive and difficult-to-treat cancers. In October 2025, the FDA expanded its approved use to include maintenance therapy in combination with other drugs for patients whose disease hasn’t progressed after initial treatment. Both trabectedin and lurbinectedin trace their chemical lineage to compounds first isolated from the tropical sea squirt Ecteinascidia turbinata.
A Sea Slug’s Contribution to Lymphoma Treatment
Brentuximab vedotin, sold as Adcetris, was approved in 2011 for Hodgkin lymphoma and a rare type of T-cell lymphoma. It’s an antibody-drug conjugate, essentially a guided missile: a laboratory-made antibody that locks onto a specific protein on cancer cells, then delivers a toxic payload inside them.
That payload is a synthetic derivative of dolastatin 10, a peptide originally isolated from the Indian Ocean sea hare Dolabella auricularia, a type of large sea slug. Dolastatin 10 is extraordinarily potent at stopping cell division by preventing the assembly of structural proteins cells need to pull apart during mitosis. On its own, it was too toxic for clinical use, but by attaching a modified version to a targeting antibody, researchers turned it into a precision therapy that concentrates its killing power on cancer cells while largely sparing healthy tissue.
Prescription Omega-3s From Fish
Not all marine drugs are exotic. Omega-3 acid ethyl esters, derived from fish oil but purified and concentrated to pharmaceutical standards, have been FDA-approved prescription drugs since 2004. Lovaza was the first, approved to treat severe hypertriglyceridemia (triglyceride levels of 500 mg/dL or higher). Several other prescription omega-3 products have followed.
These are distinct from the fish oil supplements you’d find in a drugstore. Prescription versions must meet rigorous FDA standards for purity, potency, and consistency. Studies have shown that the quality and quantity of ingredients in over-the-counter supplements varies significantly from what’s listed on the label, while prescription products do not have that problem. Your doctor might prescribe these if diet changes alone haven’t brought dangerously high triglyceride levels under control.
Why the Ocean Produces So Many Drug Leads
Marine organisms have been evolving chemical defenses for hundreds of millions of years in an environment where physical barriers like shells and thorns are often less useful than toxic molecules. Sponges, which can’t move or flee, are essentially chemical warfare factories. Cone snails need venom potent enough to instantly immobilize fish before they swim away. Tunicates compete for space on crowded reefs by producing compounds that inhibit the growth of neighboring organisms.
These pressures have generated an enormous library of structurally unique molecules. Cheminformatic analyses comparing marine and terrestrial natural products have found that marine compounds are slightly more “drug-like” overall, meaning their chemical properties align well with what’s needed to interact with human biological targets. The ocean also contains far more biological diversity than land. Entire phyla of animals, like sponges, cnidarians, and tunicates, have no terrestrial equivalents, which means their chemistry is unlike anything found in plants or land animals.
What’s Still in Development
The approved drugs represent only a fraction of what’s been pulled from the ocean. One compound attracting attention is marizomib (originally called salinosporamide A), discovered in sediment bacteria collected from the deep ocean floor by researchers at Scripps Institution of Oceanography. It has been in phase 3 clinical trials for glioblastoma, the most lethal form of brain cancer, and has also shown activity against multiple myeloma and even malaria in earlier studies.
Hundreds of other marine natural products are in various stages of preclinical and clinical testing. The pace of discovery has increased sharply in recent decades as advances in deep-sea collection technology, genomic sequencing, and synthetic chemistry have made it easier to find, identify, and manufacture these compounds. Many marine organisms produce their bioactive molecules in vanishingly small quantities, so the ability to synthesize them in the lab, as was done with eribulin, has been critical to turning ocean discoveries into usable medicines.